Phase II Study of SKB518 Alone or With Tislelizumab and Carboplatin in Adults With Lung Cancer

What this Trial Is About

Researchers are evaluating the safety, tolerability, and preliminary anti-tumor effects of SKB518 in patients with lung cancer. This open-label, multicenter phase II study includes patients with non-small cell lung cancer or small cell lung cancer who have measurable tumors. The study aims to better understand how SKB518 works alone or in combination with other drugs in this patient population. Participants receive SKB518 alone or combined with Tislelizumab or Tislelizumab plus Carboplatin. SKB518 and Tislelizumab are given every three weeks until the cancer progresses, unacceptable side effects occur, or other reasons require stopping treatment. Carboplatin is administered every three weeks for four cycles when given. The study has different treatment arms depending on lung cancer type and prior therapy. During the study, participants undergo regular assessments including imaging to check tumor response, safety monitoring for side effects, and evaluations of progression-free survival and overall survival. Researchers also study pharmacokinetics and immune response. The study lasts up to 24 months to observe treatment effects and safety over time.

A Study of SKB518 in Patients With Lung Cancer